EP3157526A1 — Oral pharmaceutical composition of tofacitinib
Assigned to Sun Pharmaceutical Industries Ltd · Expires 2017-04-26 · 9y expired
What this patent protects
The present invention relates to a dry process for the preparation of pharmaceutical compositions of tofacitinib comprising tofacitinib and one or more pharmaceutically acceptable excipients. Dry processes, such as direct compression or dry granulation, involve fewer and simpler …
USPTO Abstract
The present invention relates to a dry process for the preparation of pharmaceutical compositions of tofacitinib comprising tofacitinib and one or more pharmaceutically acceptable excipients. Dry processes, such as direct compression or dry granulation, involve fewer and simpler process steps, thus preventing the loss of the active ingredient during processing.
Drugs covered by this patent
- Xeljanz (Tofacitinib Citrate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.